Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Execs Urge Post-Brexit Regulatory Deal, As EMA Focuses On Redistribution Of MHRA Work

Executive Summary

Spurred by an apparent shift towards a more pro-business stance among government ministers, a number of top pharmaceutical executives and heads of UK industry bodies have publicly called for some form of regulatory alignment deal between the UK and the EU after Brexit.

You may also be interested in...

Brexit: Bids In For The EMA As Portugal Drops Lisbon For Porto, Bratislava Emerges As Possible Front-Runner

All bids to host the European Medicines Agency were to have been in by close of business on July 31. Portugal has unexpectedly switched its candidacy from Lisbon to Porto, Bratislava could emerge as a surprise favorite. Meanwhile the CEO of AstraZeneca has said investment decisions are being put on hold pending more clarity over Brexit.

EMA Suspends Some Activities To Focus On Brexit Relocation

The EMA has given some details of its business continuity plan for Brexit preparedness, which includes diverting some resources from lower-priority tasks to focus on core activities.

Lobbying Pays Off As UK Ministers Speak Out On Post-Brexit Regulatory Collaboration

Pressure from industry and other bodies seems to be paying off after two senior government ministers publicly called for a “close working relationship” between the UK and the EU after Brexit. The move has been welcomed by the life sciences industry, which has been lobbying for some sort of regulatory cooperation agreement to avoid regulatory divergence and possible delays to new product launches.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts